ASCO President David Johnson to oncologists: It’s time to “reconnect to our patients” and “recommit to our profession.” Horning outlines priorities.
Von Eschenbach says oncology is undergoing a “revolutionary evolution.”
CCOPs ask NCI officials about one-year extensions.
Varmus: Why are scientific societies obstructing public access to research results?
Despite NCI director’s enthusiasm, “We have a long way to go before we beat cancer,” the former NIH director says.
Onward to 2010? NCI promises faster progress for more money.
Trending Stories
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - Pancreatic cancer breakthrough came from smart scientists making smart bets—not from politicization of science
- At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
- Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.”
